Journal d'immunologie clinique et cellulaire

Journal d'immunologie clinique et cellulaire
Libre accès

ISSN: 2155-9899

Abstrait

Indoleamine 2,3-Dioxygenase (IDO); Silenced Dendritic Cell Vaccine with Ipilimumab in Treating Metastatic Melanoma Patients: A Case Report

Qing Chen, Wang Liu, Zhongbin Zhoa*

Immunotherapy has revolutionized the treatment landscape for metastatic melanoma. This case report presents the clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CTLA-4 checkpoint inhibitor, and an Indoleamine 2,3-Dioxygenase (IDO)-silenced Dendritic Cell (DC) vaccine. The treatment approach aimed to enhance antitumour immunity by blocking immune checkpoints and activating dendritic cells. The patient demonstrated a significant clinical response, indicating the diversification and potentiation of the antitumour effects. This case underscores the potential of combined immunotherapeutic strategies in achieving durable and robust antitumour effects.

Clause de non-responsabilité: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été révisé ou vérifié.
Top